Exploring brain imaging to understand neurodegeneration in multiple sclerosis
Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis: Long Term Predictive Value (IMAGIN-DEAL in MS)
This study is testing how brain imaging can help us understand the brain changes in people with multiple sclerosis who have been living with the condition for a long time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Trial ID | NCT05633875 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the biological mechanisms underlying neurodegeneration in patients with multiple sclerosis (MS) by utilizing multimodal imaging techniques such as MRI and PET-MRI. Participants, who have been part of previous studies for at least eight years, will undergo comprehensive neurological examinations, medical history assessments, neuropsychological testing, and blood sample collection for biobanking. The goal is to enhance understanding of neurodegenerative processes in MS and to identify potential biomarkers for future therapeutic strategies.
Who should consider this trial
Good fit: Ideal candidates are adults with multiple sclerosis who have been enrolled in specific previous studies for at least eight years.
Not a fit: Patients who are unable to undergo MRI due to medical contraindications or those with severe uncontrolled comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and treatment strategies for neurodegeneration in multiple sclerosis, potentially delaying disability progression.
How similar studies have performed: While this approach is innovative, previous studies have shown promise in using imaging techniques to understand MS, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Multiple Sclerosis Patient already enrolled in one of those 3 protocols since 8 years or more: INFLASEP, FLUMATEP 1-2 or SHADOWTEP * Adult patient * Affiliation to a social security scheme or beneficiary of such a scheme (Except "Aide Médicale d'Etat") * Consent obtained Exclusion Criteria: * Any reasons, which does not allow to perform MRI, including claustrophobia, the implant of a pace maker or the presence of an intra-ocular foreign body (a contra- indication questionnaire will be filled in beforehand) * Pregnancy, breast-feeding, lack of efficient contraception * Current symptoms of severe or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary or cardiac disease, or any other chronic neurological diseases * Unwillingness to be informed in case of abnormal MRI (with a significant medical anomaly) * Enrolment in another interventional study protocol for the duration of his or her participation without physician's agreement * Patient under legal protection
Where this trial is running
Paris
- CIC Neurosciences — Paris, France (Recruiting)
Study contacts
- Principal investigator: Bruno Stankoff, Pr — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Bruno Stankoff, MD
- Email: bruno.stankoff@aphp.fr
- Phone: 1 42 16 24 32
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.